Phase 1 trial is evaluating the safety and tolerability of a novel formulation of intranasal 5-MeO-DMT Study will measure detailed pharmacokinetics and metabolism of 5-MeO-DMT in healthy volunteers Preliminary data, expected H1 2022, to support Phase 2 study designs investigating the use of 5-MeO-DMT in treatment resistant depression (TRD) and other neuropsychiatric indications OXFORD, England–(…


Previous articlePsychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data
Next articleEuropean Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders